Skip to main content

1 Result(s)

within Yarong Li Remove this filter Biomedicine, general Remove this filter

and

  1. Article

    Open Access

    Long-term outcomes with HLX01 (HanliKang®), a rituximab biosimilar, in previously untreated patients with diffuse large B-cell lymphoma: 5-year follow-up results of the phase 3 HLX01-NHL03 study

    HLX01 (HanliKang®) is a rituximab biosimilar that showed bioequivalence to reference rituximab in untreated CD20-positive diffuse large B-cell lymphoma (DLBCL) in the phase 3 HLX01-NHL03 study. Here, we report th...

    Yan Qin, Yong** Song, Dong Wang, Ou Bai, Jifeng Feng, **uhua Sun, Lihua Qiu… in BMC Cancer (2024)

    Download PDF (3171 KB) View Article